announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback